Genetic variability of hepatitis B virus and response to antiviral treatments: Searching for a bigger picture

Journal of Hepatology

Volumn 50, Issue 3, 2009, Pages 445-448

  Yuen, Lilly K W ^a   Locarnini, Stephen A ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; CYTOKINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; HLA DR ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; DISEASE CONTROL; DISEASE COURSE; DRUG APPROVAL; DRUG MECHANISM; EDITORIAL; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B VIRUS; IMMUNOMODULATION; INFECTION RISK; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; OPEN READING FRAME; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SEROCONVERSION; TREATMENT RESPONSE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOME, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; OPEN READING FRAMES; VIRUS REPLICATION;

EID: 59549105956     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.12.005     Document Type: Editorial

References (31)

1. WHO. Hepatitis B fact sheet. http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed October 2008.
2. Wiegand J., Hasenclever D., and Tillmann H.L. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 13 (2008) 211-220
3. Kramvis A., and Kew M.C. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 12 (2005) 456-464
4. Liu C.J., and Kao J.H. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 13 (2008) 613-624
5. Chu C.M., and Liaw Y.F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 43 (2005) 411-417
6. Orito E., Mizokami M., Sakugawa H., Michitaka K., Ishikawa K., Ichida T., et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33 (2001) 218-223
7. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 72 (2004) 363-369
8. Nakayoshi T., Maeshiro T., Nakayoshi T., Nakasone H., Sakugawa H., Kinjo F., et al. Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study. J Med Virol 70 (2003) 350-354
9. Miyakawa Y., Okamoto H., and Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat 4 (1997) 1-8
10. Mayerat C., Mantegani A., and Frei P.C. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection?. J Viral Hepat 6 (1999) 299-304
11. Rodriguez-Frias F., Buti M., Jardi R., Cotrina M., Viladomiu L., Esteban R., et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 22 (1995) 1641-1647
12. Miyakawa Y., and Mizokami M. Classifying hepatitis B virus genotypes. Intervirology 46 (2003) 329-338
13. Sugauchi F., Kumada H., Sakugawa H., Komatsu M., Niitsuma H., Watanabe H., et al. Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. Clin Infect Dis 38 (2004) 1222-1228
14. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 (2000) 554-559
15. Farrell P.J., Sen G.C., Dubois M.F., Ratner L., Slattery E., and Lengyel P. Interferon action: two distinct pathways for inhibition of protein synthesis by double-stranded RNA. Proc Natl Acad Sci USA 75 (1978) 5893-5897
16. Gunther S., Paulij W., Meisel H., and Will H. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology 244 (1998) 146-160
17. Zampino R., Marrone A., Cirillo G., del Giudice E.M., Utili R., Karayiannis P., et al. Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment. J Viral Hepat 9 (2002) 183-188
18. Chu R.H., Ma L.X., Wang G., and Shao L.H. Influence of HLA-DRB1 alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B. World J Gastroenterol 11 (2005) 4753-4757
19. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 (1998) 1670-1677
20. Yang H., Qi X., Sabogal A., Miller M., Xiong S., and Delaney W. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10 (2005) 625-633
21. Colonno R.J., Rose R.E., Pokornowski K., Baldick C.J., Klesczewski K., and Tenney D.J. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time lamivudine refractory patients. Hepatology 44 Suppl 1 (2006) 229A
22. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
23. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008: doi:10.1007/s12072-12008-19048-12073.
24. Ogata N., Fujii K., Takigawa S., Nomoto M., Ichida T., and Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol 59 (1999) 270-276
25. Warner N., Locarnini S., Kuiper M., Bartholomeusz A., Ayres A., Yuen L., et al. The L80I Substitution in the Reverse Transcriptase Domain of the Hepatitis B Virus Polymerase Is Associated with Lamivudine Resistance and Enhanced Viral Replication In Vitro. Antimicrob Agents Chemother 51 (2007) 2285-2292
26. Yuen L.K., Ayres A., Littlejohn M., Colledge D., Edgely A., Maskill W.J., et al. SEQHEPB: A sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 75 (2007) 64-74
27. Delaney W., Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77 (2003) 11833-11841
28. Torresi J., Earnest-Silveira L., Deliyannis G., Edgtton K., Zhuang H., Locarnini S.A., et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293 (2002) 305-313
29. Svicher V., Gori C., Trignetti M., Visca M., Micheli V., Bernassola M., et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 50 (2009) 461-470
30. Gonzales M.J., Wu T.D., Taylor J., Belitskaya I., Kantor R., Israelski D., et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. Aids 17 (2003) 791-799
31. Rhee S.Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., and Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31 (2003) 298-303